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Abstract: The efficiency of haemodialysis treatment relies on a functional status of vascular access. A vascular access makes 
life-saving haemodialysis treatments possible. The efficiency of haemodialysis treatment relies on a functional status of vascular 
access. The purpose of this review was to discuss the role of haemodialysis and vascular access in end stage kidney disease. 
Vascular access and its related problems represent the main factors that determine a rise in the rate of incidence of the disease 
among haemodialysis patients and, consequently, a rise in the healthcare expenses. Vascular access can be divided into three 
categories: arteriovenous fistula, central venous catheter and arteriovenous graft. Central venous catheter has a number of 
disadvantages, including a considerable risk of infection and mortality. It also has negative implications for the use of a fistula for 
dialysis. In contrast, arteriovenous fistula is the most beneficial method, as it has a low risk of infection and mortality, and can 
ensure long-term functional access. Furthermore, there are three configurations of native arteriovenous fistula that can be used 
for haemodialysis providing flexibility of approach depending on risk factors of the individual patient.  
Keywords: Haemodialysis, Vascular Access, End Stage Kidney Disease 
 
1. Introduction 
Chronic Kidney Disease (CKD) is a critical condition with 
considerable public health implications describes as abnormal 
kidney function and/or structure [1]. Progressive and 
permanent renal failure is most frequently treated with 
haemodialysis. Since 2009, the number of patients receiving 
home haemodialysis has increased by 23%, from 636 to 780 
patients with median age of 66 years [2]. Haemodialysis has 
been used to treat renal failure since the 1960s [3]. Renal 
Replacement Therapy (RRT) with haemodialysis does not 
provide true replacement of renal function. However, by 
removing waste solutes, excess body water and restoring 
biochemical and acid-base balance, haemodialysis has 
considerably improved the morbidity and mortality of ESRD 
patients. 
The first haemodialysis performed in a human was by Haas 
in 1924 [4]. Twenty years later Willem Kolff provide a 
primitive form of vascular access, establishing effective 
anticoagulation and producing reliable equipment for 
widespread use when he created the rotating drum kidney in 
1943 [5, 6]. 
A suitable type of vascular access has to be created to 
establish a connection between the circulation system of the 
patient and the haemodialysis cycle, in order to provide 
haemodialysis in ESRD patients. There are generally three 
types of vascular access that can be used for haemodialysis. Of 
these, the AVF is considered to provide the best long-term 
functional vascular access, with a reduced risk of thrombosis or 
infection and is most cost-effective [7]. In addition, AVF does 
not necessitate multiple interventions and has a lower mortality 
and morbidity rate among different types of vascular access [8]. 
The purpose of this review was to discuss the role of 
haemodialysis and vascular access in end stage kidney disease.  
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2. Mechanism of Haemodialysis 
The current haemodialysis machine bears little resemblance 
to that devised by Kolff in 1943 although the design adheres to 
similar principles [5, 6]. This centres on removing blood from 
the intravascular compartment, passing it through an 
extracorporeal circuit into a dialyser and removing waste 
solutes and excess water by exposure to conditions that 
promote diffusion, convection, and movement in response to 
hydrostatic pressure gradients. Dialysed blood is then returned 
to the patient through the venous system. The volume of 
plasma cleared of solute per unit time by dialysis is expressed 
as the solute clearance. Diffusion is the predominant method 
by which solute clearance from plasma is achieved by 
haemodialysis. The process of diffusion is dependent upon 
blood from the extracorporeal circuit flowing through the 
dialyser, a collection of microfilament fibres bathed in 
dialysate fluid, which circulates in the opposing direction to 
blood flow. Blood is withdrawn from the fistula via the needle 
by a peristaltic pump, circulated through the dialyser, and 
returned to the fistula downstream through the needle. 
Heparin is infused downstream from the blood pump. 
These conditions are favourable to the rapid diffusion of 
solutes through pores within the microfilament fibres, down a 
concentration gradient from blood to dialysate or vice-versa. 
The rate of diffusion varies with the degree of concentration 
gradient between compartments, the surface area of the 
microfilament membrane, the number and size of pores within 
the membrane, the molecular size of the solute and the relative 
flow rates of both extracorporeal blood and dialysate [9]. 
It can be seen that key determinants in the success of 
haemodialysis are the characteristics of the selectively 
permeable membranes used to form the microfilament tubes 
within dialyser units. Membranes may now be classified by 
the type of material used in their manufacture (synthetic, 
cellulose and substituted cellulose), their capacity, surface 
area, ultrafiltration coefficient, flux and in some cases, their 
ability to be reused [10]. 
3. Functional Outcomes of Haemodialysis 
A high level of serum albumin has been considered as a 
positive measure of survival prediction in patients receiving 
dialysis due to the fact that it is an indicator of improved 
nutrition and reduced inflammatory burden [11]. Block et al. 
[12] have demonstrated that a reduced concentration of 
calcium phosphate is also a measure of increased survival rate 
as it is an indicator of efficient treatment of bone disease. 
Renal anaemia, reflected by low haemoglobin levels [13], and 
low dialysis doses [14] is associated with unsatisfactory and 
poor outcomes of haemodialysis [15].  
Arteriovenous fistula is the first option considered for the 
construction of vascular access for dialysis. The construction 
of the fistula should be undertaken at least a month prior to the 
beginning of the dialysis treatment, as specified in the 
NKF-KDOQIa guidelines [16]. By doing this, a number of 
potential problems can be prevented, including the urgent 
need for a catheter and its associated complications, such as 
infection, bleeding, thrombosis and vessel damage; 
additionally, the period spent in hospital also is reduced. 
According to Rayner et al., a fistula needs two to six weeks to 
fully mature [17]. The main objective of health care is to 
create an AVF for the majority of patients prior to formal 
haemodialysis for the first time. Among the advantages of 
native AVFs are increased blood flow, reduced risk of sepsis, 
and durability.  
4. Vascular Access 
Vascular access problems represent the main determinant of 
morbidity among haemodialysis patients and put a 
considerable degree of financial pressure on the healthcare 
sector [2, 18]. The three types of constructions of AVFs, which 
are usually employed, are radiocephalic, brachiocephalic and 
brachiobasilic. The pre-surgery non-invasive scan imaging 
help clinicians in the decision making process as to which of 
these three types would be more suitable for the patient. Often, 
more than one type could be suitable and the one that is 
believed to have a higher success rate is chosen. However, 
when all three options are on the same level of success, a 
number of other aspects are included in the decision making, 
such as using the non-dominant arm or a more distally placed 
fistula (radiocephalic) to allow in future an easier formation of 
proximal fistula (brachiocephalic or brachiobasilic) and 
forming a brachiocephalic fistula over a brachiobasilic fistula 
due to its ease of formation and less surgical stress. 
4.1. Type of Vascular Access 
Successful haemodialysis depends on the provision of safe, 
efficient, and durable vascular access. Establishing and 
maintaining effective vascular access is a demanding process 
for both patients and renal services. These demands are set to 
increase in response to an RRT population that is becoming 
increasingly dependent on haemodialysis, whilst also 
increasing in population size, age, and co-morbidity. 
Initially, vascular access methods relied on repeated 
peripheral cannulation to deliver arterial blood to the dialysis 
machine and return it to an accompanying vein. In 1949, 
Alwall, made the first attempt to connect an artery and a vein, 
using glass cannula and rubber tubing [6, 19]. This device 
would allow blood to be diverted onto an extracorporeal 
circuit for dialysis when required. His attempt was 
unsuccessful although it provided the template for the 
arteriovenous Teflon Shunt developed by Quinton et al. [20]. 
Their device consisted of two Teflon cannula inserted into the 
wrist, one in the branch of the brachial artery in the forearm 
and one in the accompanying antecubital vein. The cannula 
had its external ends connected by flexible tubing from which 
connection to an extracorporeal circuit could be made. This 
provided nephrologists with the first permanent vascular 
access device and was a decisive breakthrough in the 
provision of haemodialysis to the ERF population. The 
‘Scribner’ shunt, as it came to be known, underwent many 
refinements before being ultimately superseded by the 
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successful development of arteriovenous fistulae, 
arteriovenous grafts, and central venous catheters. 
Nonetheless, the Scribner shunt played a key role in the 
development of permanent vascular access devices. 
4.1.1. The Arteriovenous Fistula 
Cimino and Brescia described a technique where 
haemodialysis was conducted through a simple puncture of 
the most accessible forearm vein. Patency of the vein was 
assured by the use of an inflatable tourniquet. This allowed 
needles of varying sizes to be used with resultant 
haemodialysis flows of 150-400 ml/min. Whilst successful, 
this technique was limited by the poor longevity of peripheral 
veins in comparison with that of Scribner’s external 
arteriovenous shunt. Logical development of this technique, 
however, led to the creation of the first internal arteriovenous 
fistula. The successful use of the new technique was reported 
in a landmark paper [21]. The thought process of AVF was 
based on Cimino treating veterans of the Korean war; some of 
whom had traumatic AVF due to gunshot wounds and Cimino 
noted that venesection in these patients was very easy. They 
reported 12 cases in which successful primary function of an 
AVF had been achieved by creating a side-to-side connection 
at the wrist between the cephalic vein and radial artery. 
Exposure to high-pressure arterial flow was found to promote 
enlargement and thickening of the venous wall. After 
approximately six weeks maturation, a robust vessel wall had 
developed that could sustain repeated cannulation and allow 
regular haemodialysis to take place. 
Arteriovenous fistula created by connecting an artery 
directly to a vein, frequently in the forearm. This artificial 
connection allows the vein to become larger and for the walls 
of the vein to thicken, a process termed maturation. A year 
later the technique had been amended to allow the 
construction of an end-to-end anastomosis in the lower arm 
between the cephalic vein and the radial artery [22]. This 
technique restricted arterial inflow into the AVF to that blood 
delivered by the feeding radial artery led to a high risk of 
developing steal syndrome.  
This is a clinical condition caused by arterial insufficiency 
distal to haemodialysis AVF due to diversion of blood into 
AVF. Consequently, the technique latterly became regarded as 
a secondary option available to surgeons when considering 
surgical revision of a failed AVF. It is the technique that has 
become the standard AVF creation procedure of choice and 
has allowed AVF creation surgery to evolve and successfully 
provide a range of potential sites for AVF creation, 
predominately within the upper limbs [6].  
Upper arm fistulae are more likely to cause ischemic 
symptoms compared to forearm fistulae. The presence of poor 
peripheral vasculature secondary to diabetes, calcification and 
peripheral arterial disease is the primary etiological factor. For 
practical purposes AVF creation is best conducted on the 
non-dominant arm with use of distal sites where possible; 
preserving the proximal vascular tree should vascular access 
surgery be required in the future. The longevity, durability, 
and favourable complication rate of the AVF have established 
it as the leading method of establishing permanent 
haemodialysis vascular access. Around two thirds of 
haemodialysis patients in the UK dialyse using an AVF [23]. 
4.1.2. Arteriovenous Grafts 
An alternative to the AVF is the synthetic arteriovenous 
graft (AVG). This was devised following the introduction of 
the Scribner shunt, which was noted to employ a length of 
flexible tubing to connect the arterial and venous blood flow. 
Thomas [24] developed this principle by replacing the cannula 
with Dacron patches sutured into the vessel wall and bringing 
out a loop of connecting silastic material to the skin surface. 
By avoiding the use of intraluminal cannula, this device was 
less prone to thrombosis. Meanwhile, the first vein graft had 
been performed using a length of excised saphenous vein, to 
connect the brachial artery to its accompanying vein. By 
combining each of these three principles direct anastomosis of 
vessels to tubing, looping a section of tubing to connect artery 
to vein and subcutaneous tunnelling of the connecting loop, 
the modern AVG was created [6]. Whilst initially Dacron was 
the most commonly used graft material, the emergence of the 
synthetic material polytetrafluoroethylene (PTFE) as a pliable, 
biocompatible material that may be repeatedly cannulated yet 
maintain its structural integrity, led to significant 
improvement in the durability of the AVG.  
The brachial artery and the basilic vein are usually 
connected by way of an AVG. However, it is also common to 
connect the radial artery and the basilic vein or the brachial 
artery and the axillary vein with the use of grafts. When 
vascular access in the upper limbs is exhausted, synthetic 
grafts can be used to establish vascular access using the 
subclavian or axillary vessels, femoral vessels, or may even be 
anastomosed between the arterial system and the right atrium. 
Approximately 3% of haemodialysis patients in the UK 
dialyse via an AVG at present [23]. 
4.1.3. Central Venous Catheters 
In the early years of haemodialysis, the demand for 
experienced surgeons to create arteriovenous shunts, fistula 
and grafts outstripped supply. The paucity of vascular and 
transplant surgeons prepared to perform these procedures 
provoked one UK nephrologist, Stanley Shaldon, to develop 
hand-made cannulae that could undergo insertion into the 
femoral artery and accompanying vein to permit immediate 
haemodialysis access. He made use of the Seldinger insertion 
technique - a method that enables safe catheter placement into 
the vascular tree introduced [24]. 
It was noted that arterial cannulation, in contrast to venous 
cannulation, is accompanied by an abnormally high risk of 
bleeding and was soon abandoned. Gradually different 
insertion sites were used including the jugular and subclavian 
veins. These had the advantage of allowing central venous 
pressures to be estimated in patients with extracellular fluid 
depletion [26], a common occurrence in many individuals 
suffering from acute kidney failure requiring dialysis. The 
insertion of a cannula into the subclavian vein became the 
favoured approach for CVC insertion until the early 1990s 
when angiographic data demonstrated a significantly 
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increased risk of central venous stenosis at the site of 
cannulation. This predisposed patient to a high risk of limb 
oedema, which could impair the ability to create and maintain 
a functioning AVF [27]. 
Insertion into the internal jugular veins is now regarded as 
standard practice although femoral venous cannulation is also 
performed. CVCs are frequently used temporarily to provide 
vascular access for haemodialysis whilst the patient awaits 
creation or maturation of an AVF or AVG or because they have 
run out of suitable options for permanent vascular access [28]. 
Some CVCs may be tunnelled subcutaneously en-route to 
entering the vein with a securing cuff to stabilise the position 
of the catheter and reduce potential for periluminal infection. 
Direct transcutaneous cannulation of the vein is often 
performed acutely and tends not to involve subcutaneous 
tunnelling or use of a securing cuff. Polyurethane and silicone 
are the two materials most commonly used in the manufacture 
of haemodialysis catheters although polymers such as 
carbothane are increasingly common [29]. These materials 
provide sufficient flexibility, durability, and biocompatibility 
for intravascular use. 
The catheters are the least preferred modality and, in an 
ideal setting, no patient should have a catheter as access. 
Despite the risks associated with dialysis catheters, their use 
has increased to almost 70% of incident dialysis initiation with 
catheters [30]. The different methods of obtaining vascular 
access allow haemodialysis to be a viable treatment for most 
of ESRD patients. The diversity of vascular access options 
available can help nephrologists address a range of clinical 
scenarios more effectively. Late presentation of ESRD is one 
frequently experienced scenario that may have a significant 
impact on vascular access provision. In this setting, the time in 
which RRT is required to start may arrive before the patient 
can undergo vascular assessment, surgery, and successful 
maturation of their fistula. This phenomenon is often used to 
explain the relatively high prevalence of ESRD patients using 
CVCs as their first haemodialysis access modality. In the UK 
renal registry vascular access survey of 2006, 66% of patients 
started haemodialysis on a CVC compared with 34% using an 
arteriovenous fistula or an arteriovenous graft. After one year, 
the percentage of individuals treated with a CVC reached 28% 
compared with 71% using an AVF or AVG [23]. UK Renal 
Association [2] suggested that 2/3 of all patients requiring 
dialysis should start with an autologous fistula and the 
remaining 1/3 with CVC as these are described as the “Crash 
Landers” who have acute or undiagnosed renal failure and do 
not have time for AVF creation and maturation. Similarly, 
when an AVF or AVG fails, CVCs are a rapid means of 
establishing vascular access and thus play a significant part in 
providing urgent vascular access.  
4.2. Functional Outcomes of Vascular Access 
As noted by several researchers [31, 32], surgical interventions 
of vascular access and their associated problems are important 
causes of morbidity, hospitalisation, and financial pressure. In the 
US, more than 20% of the total number of haemodialysis patients 
were admitted to hospital as a result of vascular access and its 
complications. The costs generated annually amounts to almost 
$1 billion [31]. Studies have shown that dialysis grafts made of 
PTFE are not as long lasting as autologous fistulae [33, 34]; 
furthermore, they are more likely to develop repeated thrombosis, 
stenosis, and infection. The NKF-KDOQIa guidelines [16] 
recommend the use of AVFs over AVGs due to the advantages of 
the fistula; the AVGs should only be employed when the creation 
of natural AVFs is due to the exhaustion in the use of the patient’s 
veins.  
Clearly, there are logistical hurdles to this late presentation to 
renal services, fitness for surgery, suitable peripheral vascular 
anatomy, delays due to primary or secondary access failure and 
slow rates of AVF maturation. Consequently, there remain 
situations, especially when starting RRT, where use of an AVG or 
CVC may be required. This is demonstrated by the relative 
prevalence of CVC use in patients starting RRT around the world. 
Similarly, CVC insertion is the mainstay of vascular access 
provision to the acute renal failure population who require 
haemodialysis. There is a strong association between catheter use, 
comorbidity, and in-patient care. The question of whether the 
adverse features related to catheter use, such as catheter 
thrombosis and bacteraemia, are specifically related to use of a 
catheter or are simply related to the greater level of comorbidity 
expressed by the population who require catheter insertion has 
been subject to controversy [35].  
Catheters are prone to develop infection from 3.8 to 5.5 
episodes per 1000 days [36]. Infection can be localized or spread 
systematically leading to bacteraemia or sepsis [37]. In AV graft 
or within its outflow vein where the graft stitched to the vein, 
stenotic lesions are found time and again [38]. The underlying 
mechanism is the marked increase in shear stress in the 
thin-walled outflow vein, which activates focal fibromuscular 
hyperplasia and initiates a fibrotic venous lesion to develop 39. 
5. Conclusion 
A vascular access makes life-saving haemodialysis treatments 
possible. The efficiency of haemodialysis treatment relies on a 
functional status of vascular access. Each access type 
(CVC/AVG/AVF) has its relative attributes, it is important to 
consider the differing degrees of reliability, durability, and 
complications associated with each approach. Whether 
considering an individual patient’s circumstances or planning 
vascular access provision at a population level, understanding the 
range of complications expressed by each access type and which 
factors predispose to these complications is of fundamental 
importance in deriving maximum benefit with minimal risk. 
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